Clinical Trials Browser

Phase 2 × Multiple Myeloma × Injections × Clear all

NCT07085728 2025-08-22

Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

Phase 2 Not yet recruiting

Multiple Myeloma

NCT01125449 2025-05-18

Study of High Dose Intravenous (IV) Ascorbic Acid in Measurable Solid Tumor Disease

Phase 2 Withdrawn

Plasma cellSarcoma

Adenocarcinoma, Carcinoma, Multiple Myeloma, Sarcoma, Desmoplastic Small Round Cell Tumor

NCT01660633 2020-04-21

Safety & Efficacy Study High Dose Evomela Injection for MA Conditioning in MM Patients With Autologous Transplantation

Phase 2 Completed

Multiple Myeloma

NCT00925782 2019-12-17

PK Study of Melphalan HCL & Alkeran for Injection of MA Conditioning in MM Patients of Autologous Transplantation

Phase 2 Completed

24 enrolled 10 charts

Multiple Myeloma

NCT02669615 2018-10-10

Pharmacokinetic Study of Propylene Glycol-Free Melphalan HCl for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation

Phase 2 Completed

24 enrolled 6 charts

Multiple Myeloma

NCT01148108 2013-03-15

Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma

Phase 2 Completed

LymphoidPlasma cell

Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Lymphoma, B-Cell, Lymphoma, Mantle-Cell